Category: Uncategorized
Vericel inks licensing deal for MediWound’s NexoBrid, posts Q1 earnings
| Mass Device

Vericel (NSDQ:VCEL) said yesterday it inked an exclusive U.S. licensing and supply agreement with MediWound (NSDQ:MDWD) for its NexoBrid biological product, and reported first quarter earnings that missed expectations on Wall Street. The NexoBrid is a topically-administered product intended to enzymatically remove nonviable burn tissue in patients with deep partial and full-thickness thermal burns. The product has already […]

Chemotherapy Development is ‘In’ Again
| Applied Clinical Trials

Cancer therapy development has advanced to researching targeted immunotherapies and are moving into gene-specific therapies.  Some companies, however, are focusing on reviving cytotoxic therapies that were too toxic for patients when administered generally. These companies are developing targeted transportation mechanisms to deliver cytotoxic release at tumor cells while minimizing overall toxicity to patients. Bill Newell, Chief […]

Weekly Infusion May Be Effective, Easier HIV Therapy
| Healthy Day

The advent of highly active antiretroviral therapy (HAART) in the 1990s revolutionized HIV/AIDS treatment. But while it dramatically improves survival, some patients can develop troublesome side effects or even resistance to the potent pills. So, the search for an alternative has continued. Enter UB-421. An antibody that is infused into the bloodstream, this new compound […]